TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject or legally appointed and authorized representative must have read, understood and signed an Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form and must be able to and willing to follow study procedures and instructions.~2. Age ≥ 6 months and older at the time of Informed Consent.~3. Clinical diagnosis of the Dystrophic Epidermolysis Bullosa.~4. Confirmation of DEB diagnosis (either DDEB or RDEB) by genetic testing including COL7A1.~5. Two (2) cutaneous wounds meeting the following criteria:~   1. Location: similar in size, located in similar anatomical regions, and have similar appearance~  2. Appearance: clean with adequate granulation tissue, excellent vascularization, and do not appear infected.~6. Subjects and caregivers who, in the opinion of the Investigator, are able to understand the study, co-operate with the study procedures and are willing to return to the clinic for all the required follow-up visits.~7. Male or Female of childbearing potential must use a reliable birth control method throughout the duration of the study and for three (3) months post last dose of B-VEC.~8. Negative pregnancy test at Visit 1 (Week 1), if applicable.~Exclusion Criteria:~1. Medical instability limiting ability to travel to the Investigative Center.~2. Diseases or conditions that could interfere with the assessment of safety and efficacy of the study treatment and compliance of the subject with study visits/procedures, as determined by the Investigator.~3. Current evidence or a history of squamous cell carcinoma in the area that will undergo treatment.~4. Subjects actively receiving chemotherapy or immunotherapy at Visit 1 (Week 1).~5. Active drug or alcohol addiction as determined by the Investigator.~6. Hypersensitivity to local anesthesia (lidocaine/prilocaine cream).~7. Participation in an interventional clinical trial within the past three (3) months (not including BVEC administration).~8. Receipt of a skin graft in the past three (3) months.~9. Pregnant or nursing women.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B-VEC (Type: EXPERIMENTAL): Topical gel of non-integrating, replication-incompetent HSV-1 expressing the human collagen VII protein
- Placebo (Type: PLACEBO_COMPARATOR): Matching masked inactive topical gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has primary hypercholesterolemia or mixed dyslipidemia (high cholesterol)~* Participant is a non-smoker~Exclusion Criteria:~* Participant has a history of chronic seizures~* Participant has a history of cancer~* Participant has a history of stomach or intestinal ulcers or any history of GI bleeding~* Participant has had major surgery, donated blood or participated in another investigational study in the past 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Period 1 (Type: EXPERIMENTAL): In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
- Period 2 (Type: EXPERIMENTAL): In Periods 1 and 2 each participant will receive one of the following treatments in a randomized crossover fashion: Treatment A (aspirin 81 mg, clopidogrel 75 mg and laropiprant 40 mg once daily for 7 days) or Treatment B (aspirin 81 mg, clopidogrel 75 mg and placebo to laropiprant 40 mg once daily for 7 days).
- Period 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* CKD stage 1 patients~* Older than 18 years of age~* Type 2 Diabetic patients~* Proteinuria~Exclusion Criteria:~* History of coronary artery disease~* Smokers~* Taking statins or renin-angiotensin blockers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female asthmatics \> 19 years of age~* baseline methacholine PC20 less than or equal to 4mg/ml~* baseline lung function \>65% predicted~* non-smoker and less than 10 pack year smoking history~Exclusion Criteria:~* use of anticholinergic within 30 days of Visit 1~* poorly controlled asthma~* pregnant or nursing~* respiratory illness within 4 weeks of Visit 1~* exposure to an agent that triggered asthma worsening (e.g. allergen) within 4 weeks of Visit 1

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tiotropium (Type: EXPERIMENTAL): 2 inhalations of 2.5mcg/inhalation tiotropium from Respimat inhaler and 1 inhalation of placebo from Breezehaler 1 hour prior to methacholine challenge
- glycopyrronium (Type: EXPERIMENTAL): 1 inhalation of 50mcg glycopyrronium from Breezehaler and 2 inhalations from placebo Respimat inhaler 1 hour prior to methacholine challenge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Edaravone-Sodium Ozagrel Comparative Post-Marketing Study on Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients can be receive drug treatment within 24 hours after stroke onset~2. Patients with a level of consciousness between 0 (alert) and 3 (unable to recall name and date of birth) according to the Japan Coma Scale~3. Patients with motor dysfunction of upper and/or lower extremities~4. Patients aged 20 years or older when giving informed consent~Exclusion Criteria:~1. Serum creatinine of \>1.5 mg/dL~2. Embolic infarction~3. Intracranial haemorrhage~4. Large infarction with severe consciousness~5. Transient ischemic attack (TIA)~6. A modified Rankin Scale score of ≥2 before stroke onset~7. Patients were receive drug treatment (argatroban, urokinase, tissue plasminogen activator, heparin, warfarin sodium, aspirin, ticlopidine hydrochloride, cilostazol, edaravone and sodium ozagrel) after stroke onset~8. Patients were receive surgical treatment or intravascular treatment~9. With severe complications (cirrhosis, heart failure, etc.)~10. Treating malignant tumor~11. Pregnant or possibly pregnant women, nursing mothers~12. History of edaravone, sodium ozagrel and ozagrel hydrochloride sensitivity~13. Less than 3 months since any other clinical trial or postmarketing study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Edaravone (Type: EXPERIMENTAL): None
- Ozagrel (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Nitroglycerin Ointment on Mastectomy Flap Necrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who undergo SSM or NSM with immediate alloplastic or autologous breast reconstruction~* Unilateral and bilateral cases (in bilateral cases only the mastectomy performed by the general surgeon will be included. This will avoid the potential effect of absorption of nitroglycerin from one breast to the other)~* Patients older than 21 and less than 65~Exclusion Criteria:~* Patient declining inclusion in the study~* Patient with medical history that precludes the administration of nitroglycerin, i.e. a medical history significant for~  * Acute circulatory failure accompanied by clear hypotension~ * Myocardial insufficiency related to obstruction~ * Use of sildenafil, vardenafil \& tadalafil~ * Use of beta-blockers, calcium channel blockers, diuretics or phenothiazides~ * Salicylates (ASA)~ * Alteplase~ * Recent history of MI or cardiac insufficiency~ * Anemia, severe~ * Cerebral hemorrhage or recent head trauma~ * Glaucoma~ * Hepatic function impairment, severe~ * Hyperthyroidism~ * Hypertrophic cardiomyopathy~ * Hypotension~ * Sensitivity to nitrites~* Patient with a history of mantle radiation~* Patient with an allergy to polysporin or any of its ingredients

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Polysporin Control (Type: PLACEBO_COMPARATOR): Patients in control group will receive polysporin ointment application. Polysporin ointment will be made to look like Nitroglycerin ointment.
- Nitroglycerin (Type: ACTIVE_COMPARATOR): Patients in treatment group will receive nitroglycerin ointment application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Patients diagnosed as having systemic JIA based on the International League of Associations for Rheumatology criteria (1997)~* Patients between 2 and 19 years of age~* Patients who are under 16 years of age at onset~* Patients who have been treated with corticosteroids (continued treatment for 3 months or longer at a dose of ≥0.2 mg/kg as prednisolone equivalent) but who failed to respond adequately or in whom treatment could not be continued or the dose could not be increased due to adverse drug reactions~Exclusion criteria~* Patients who have been treated with infliximab or etanercept within 12 weeks before treatment with the investigational product~* Patients who have received the following treatments within 4 weeks before treatment with the investigational product~  1. Surgical treatment (e.g., operation)~ 2. Plasma exchange therapy

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Contrast of Buffered Vs. Unbuffered Lidocaine in Bone Marrow Biopsies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any newly diagnosed patient at the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute whose Hematologist or Oncologist has ordered them to undergo a bilateral bone marrow biopsy for diagnostic and /or treatment purposes.~* 18 years of age or older.~Exclusion Criteria:~* Pregnant or Lactating women.~* Patients with allergies to local anesthetics.~* Patients requiring a unilateral bone marrow biopsy.~* Patients that cannot lie flat in either the supine or prone position.~* Patients that have used any of the following: narcotics, non-narcotic analgesia or an anti-anxiolytic medication on the same calendar day as the scheduled procedure. These medications will not be given to the participant at any time before or during the procedure.~* Patients on long-acting narcotic medication.~* Patients with neuropathy in the posterior iliac crest area~* Patients with a platelet count less than 20,000.~* Patients who are cognitively impaired or unable to self-report pain using the VAS.~* Patients with known bone metastasis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- buffered lidocaine (Type: EXPERIMENTAL): Sodium bicarbonate is a buffering additive that decreases the pH of the solution allowing for decrease in pain upon filtration.
- unbuffered lidocaine (Type: EXPERIMENTAL): lidocaine is injected without sodium bicarbonate added

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lippia Alba for Migraine Prophylaxis and Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine diagnostic~Exclusion Criteria:~* Patient's request

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lippia alba (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hespecta Vaccination in HPV+ Tumors or Malignant Lesions

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically documented evidence of HPV16 positive (pre)malignant lesion following standard treatment~2. Patient with a tumor should have no evidence of residual disease based on physical examination at the completion of curative intent therapy~3. At least four weeks and less than twelve weeks after last anti-tumor treatment~4. Willing and able to comply with the protocol and to provide informed consent in accordance with institutional and regulatory guidelines~5. Patients must be 18 years or older.~6. Patients of child-bearing potential should test negative using a serum pregnancy test and agree to utilize effective contraception during the entire treatment and follow-up period of the study (up to 2 months after the last vaccination)~7. Patients must be in good general health and ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1~Exclusion Criteria:~1. Radiotherapy, chemotherapy or other potentially immunosuppressive therapy administered within 4 weeks prior to the enrolment visit~2. History of an autoimmune disease or other systemic intercurrent disease that might affect the immunocompetence of the patient, or patients receiving immunosuppressive therapy, except for topical application~3. History of a second malignancy except curatively treated low-stage tumors with a histology that can be differentiated from the current tumor or premalignant lesion~4. Receipt of another investigational product within the previous 4 weeks or at any time during the study period.~5. Receipt of prior HPV directed immunotherapy~6. Hematology and biochemistry:~   * Absolute Neutrophil Count (ANC) \< 1.5 x 109/L, or platelet count \< 100 x 109/L or hemoglobin \< 6 mmol/L.~  * Serum (total) bilirubin \> 2 x upper normal limit (ULN);~  * Aspartate Aminotransferase (ASAT) or Alanine Aminotransferase (ALAT) \> 2.5 x ULN;~  * Alkaline phosphatase levels \> 2.5 x ULN;~  * Serum creatinine \> ULN or calculated clearance \</= 40 mL/min/1.73 m2 for patients with serum creatinine levels above the institutional normal value~7. Human immunodeficiency virus (HIV), chronic hepatitis B or C infection.~8. Any condition that in the opinion of the investigator could interfere with the conduct of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hespecta (Type: EXPERIMENTAL): Four dose groups of Hespecta

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Understand and voluntarily sign an informed consent form.~* Age ≥18 years at the time of signing the informed consent form.~* Diagnosis of any monoclonal gammopathy: Monoclonal Gammopathy of Undetermined Significance (MGUS), asymptomatic / active multiple myeloma, asymptomatic / active Waldenstrӧm Macroglobulinemia (WM).~Exclusion Criteria:~* Any serious egg allergy or prior serious adverse reaction to an influenza vaccine.~* Use of any other influenza vaccine for the 2015 to 2016 flu season.~* Women who are pregnant or plan to become pregnant in the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Fluzone High Dose Vaccine then Fluzone High Dose Booster (Type: EXPERIMENTAL): Fluzone High dose vaccine administered at Day 0. Fluzone High dose vaccine administered as a booster after 30 days from the initial vaccine.
- Standard of Care (Type: ACTIVE_COMPARATOR): Fluzone High-Dose if age greater than or equal to 65 or Standard dose influenza vaccine if age less than 65 at day 0. Placebo administered 30 days after the initial vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Patient with PBC defined by 2 in 3 of the following criteria: a.Positive antimitochondrial antibody type M2; b.Abnormal serum alkaline phosphatases (ALP \> 1,5N) and aminotransferase (AST/ALT \> 1N) activities; c.Histological hepatic injuries consistent with PBC.~Exclusion Criteria:~1. Pregnancy or desire of pregnancy.~2. Breast-feeding.~3. Co-existing liver diseases such as acute or chronic viral hepatitis, alcoholic liver disease, choledocholithiasis, autoimmune hepatitis, biopsy-proven non-alcoholic fatty liver disease, Wilson's disease and hemochromatosis~4. History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).~5. History of urolithiasis, nephritis or renal failure (clearance of creatinine \< 60 ml/mn).~6. Hepatotoxic drugs use before recruiting.~7. Fenofibrate anaphylaxis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Fenofibrate + UDCA (Type: EXPERIMENTAL): Fenofibrate (200 mg/day) in combination with ursodeoxycholic acid (13-15 mg/kg/day)
- Monotherapy (Type: ACTIVE_COMPARATOR): UDCA 13-15mg/kg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Patient completed the ECU-NMO-301 trial~2. Patient has given written informed consent~Key Exclusion Criteria:~1. Patients who have withdrawn from the ECU-NMO-301 trial as a result of an AE related to trial drug~2. Female patients who are pregnant, breastfeeding, or intend to conceive during the course of the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Eculizumab intravenous infusion every two weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete